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Abstract: The pathophysiology of several conditions including heart failure is partly attributable to a failure of the cell 
energy metabolism. Studies have shown that exercise training (ET) improves quality of life (QOL) and is beneficial in 
terms of reduction of symptoms, mortality and duration of hospitalization. Increasingly, ET is now achieving acceptance 
as complimentary therapy in addition to routine clinical practice in patients with chronic heart failure (CHF). However, 
the mechanisms underlying the beneficial effects of ET are far less understood and need further evaluation. Evidence 
suggests that while CHF induces generalized metabolic energy depletion, ET largely enhances the overall function of the 
heart muscle. Hence, research efforts are now aiming to uncover why ET is beneficial as a complimentary treatment of 
CHF in the context of improving endothelial function and coronary perfusion, decreasing peripheral resistance, induction 
of cardiac and skeletal muscle cells remodeling, increasing oxygen uptake, substrate oxidation, and resistance to fatigue. 
Here we discuss the current evidence that suggest that there are beneficial effects of ET on cardiac and skeletal muscle 
cells oxidative metabolism and intracellular energy transfer in patients with CHF.  
Keywords: Heart failure, exercise training, proinflammatory cytokines, nitric oxide, myocardial function, ventilatory function, 
quality of life. 
INTRODUCTION 
  Chronic heart failure (CHF) is a common condition with 
poor prognosis [1]. CHF is characterized by the inability of 
heart muscle to meet tissue energy demand that results in 
symptoms of fatigue or dyspnoea initially on exertion and 
then later on progressing to even at rest [1-2]. Actually, 
ventricular dysfunction is usually the major component of 
the CHF syndrome, which occurs in conjunction with 
skeletal muscle structural and functional abnormalities [3-4]. 
There is also a perception that the underlying mechanisms 
are largely dependent on oxidative energy production and 
control of energy fluxes [3-4]. Likewise, dyspnoea appears 
to be more closely related to increased ventilatory effort than 
pulmonary congestion, a feature that varies between patients 
[5-6].  
  The current perception is that CHF is a paradigm of 
energetic failure affecting cardiac and skeletal muscles, pro-
gressing to contractile failure, worsening physical disability, 
and eventually death. This radical shift in concept is 
supported by the change from treatment with sympathomi-
metic drugs to beta blockers. Given that in late 1980’s 
decreased left ventricular systolic function, cardiac enlarge-
ment and heart failure were considered absolute or relative 
contraindication to ET, it is now increasingly apparent that 
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the lack of physical activity leads to skeletal muscle atrophy, 
exercise intolerance, venous thrombosis & pulmonary 
embolism [7]. Therefore, the use of ET in the treatment of 
CHF is being readdressed in the context of improving endo-
thelial function, coronary perfusion, decreasing peri-pheral 
resistance, inducing cardiac and skeletal muscle cell remode-
ling, increased oxygen uptake and resistance to fatigue [8]. 
  It is unclear however, as to what extent the observed 
beneficial effects of ET in CHF patients are based on cardiac 
improvement. Whether exercise therapy improves cardiac 
and skeletal muscle cells energy metabolism of patients with 
CHF is unknown. Here, we review the role of exercise 
therapy in the management of patients with CHF. In this 
review, focus is on the different modes of ET, duration, exer-
cise dynamics in the context of cardiac rehabilitation and 
heart failure. Finally, we also present current knowledge on 
the effects of ET on changes to energy metabolism for 
chronic heart failure patients. 
CHF AND UNDERLYING MECHANISMS OF 
PROPAGATION 
Deranged Energy Metabolism  
  In normal circumstances, heart muscle maintains blood 
circulation in states of both rest and high peripheral demand 
a process that requires the transfer of vast amounts of energy 
between various compartments. The energy transfer process 
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highly efficientt. In contrast, the failing heart has been 
described as energy starved [9]. In the early stages of heart 
failure, its oxidative capacity decreases and the energy trans-
fer and utilization get impaired [10]. Heart muscle fibers 
mainly rely on mobilisable energy sources to develop strong 
and long-term contractile activity via oxidative phosphory-
lation. Because of limited cellular metabolic reserves 
(mainly phosphocreatine (PCr) and glycogen), fatigable 
muscle exhibit delayed recovery of their energy reserves 
(through anaerobic glycolysis and less importantly mito-
chondrial oxidation). The metabolic specificity of muscle 
types generates fiber-type specific substrate utilization. In 
general, oxidative fibers and cardiac muscle oxidize fatty 
acids and lactate, while glycolytic fibers mainly use glucose 
as substrate [11]. Creatine kinase (CK) and other phos-
photransfer kinases (like myokinase) participate in this 
energy shuttling within cardiac and skeletal muscle cells [12-
13] and utilize myosin and sarcoplasmic reticulum ATPases 
(SERCA). Energy is channeled directly between mitochon-
dria and the sarcoplasmic reticulum (SR) or myofibrils in 
slow skeletal and cardiac muscle to produce compartments 
of the adenine nucleotides [14].  
  Another recent development in the understanding of 
energy metabolism has been in the area of the transcriptional 
regulation and signaling pathways involved in the mainte-
nance of energy homeostasis and mitochondrial biogenesis 
for the failing heart [15]. The mitochondrial transcription 
factor (mtTFA) is encoded by the nuclear genome and 
activates the transcription and replication of mitochondrial 
DNA. The expression of mfTFA is controlled by the nuclear 
respiratory factors (NRFs) that additionally stimulate the 
expression of numerous nuclear-encoded mitochondrial pro-
teins under the control of transcriptional co-activator PGC-
1 (transcriptional co-activator of peroxisome-proliferator-
activated-receptor (PPAR) gamma) [16-19]
 PGC-1 coordi-
nates mitochondrial protein expression and substrate 
utilization by co-activating PPAR that regulates fatty acid 
oxidation and transcription of nuclear and mitochondria-
encoded proteins. Finally, pressure overload-induced hyper-
trophy results in deactivation of PPAR and subsequently 
dysregulation of fatty acid oxidation enzyme gene expres-
sion [20]. However, which signal triggers the drop in 
creatine kinase in heart failure, remains to be established. 
Inflammatory Process  
  Evidence suggests a state of heightened immune 
activation in CHF. [21-22] Pro-inflammatory cytokines 
interleukin-2 (IL-2), Interleukin-6 (IL-6), and tumour 
necrosis factor- (TNF-) are found in higher concentrations 
in the circulating blood of ischaemic heart disease and CHF 
patients compared with normal subjects [23]. Studies have 
demonstrated that TNF- can depress myocardial contrac-
tility and induce cardiomyopathy on its own [24]. Cytokines 
including TNF- promote over expression of inducible nitric 
oxide synthase [25], cause elevated levels of intracellular 
nitric oxide that are sufficient to depress oxidative capacity 
and myocardial function. Moreover cytokines including 
TNF-, are stimulators of apoptotic cell death [21-22]. The 
basis for the heightened immune response in heart failure is 
yet to be elucidated, however possible mechanisms postu- 
 
lated include tissue hypoxia [22], myocardial oxidative stress 
production and endo-toxin mediated stimulation [26-27]
 as 
summarised in Fig. (1). 
RELEVANCE OF EXERCISE TRAINING IN CHF 
  “Respiratory muscle deoxygenation” implies that ventila-
tion/perfusion mismatching is caused by the diaphragm and 
intercostal muscle metabolic impairments. While these exist, 
ventilation/perfusion mismatching is caused largely by an 
impaired cardiac output response to exercise [7]. Evidence 
demonstrates that ET is associated with lowering con-
centration of inflammatory markers including C-reactive 
protein (CRP), TNF-, and Serum amyloid A (SAA) in 
patients’ with CHF [28-29]. Mechanisms responsible for the 
anti-inflammatory effects of ET are not fully elucidated; 
however fat loss, [28] changes in CRP concentration, [28] 
increased anti-inflammatory cytokines in the peripheral 
blood mononuclear cells, [30] and increased antioxidant 
capacity in skeletal muscle [31] contribute to such effects.  
  ET in CHF works by many factors and trials demonstrate 
that peak oxygen uptake (VO2) is reduced in CHF patients 
[7]. The rationale for the reduced VO2 in HF includes a 
lower exercise cardiac output response, reduced nutrient 
blood flow to the active skeletal muscles, along with skeletal 
muscle abnormalities such as a reduced percentage of type-I 
fibres, weakened oxidative capacity and a reduction in the 
capillary density [7]. Skeletal muscle biopsy studies have 
established defects in oxidative and glycolytic enzymes that 
explain the metabolic abnormalities [32-33]. These histolo-
gic and metabolic disorders are in part similar to those seen 
in severe deconditioning and can be at least in part prevented 
by regular ET [34]. These metabolic abnormalities explain 
changes such as early fatigability and reduction in maximal 
strength that are very common in heart failure [35]. 
  However, due to concerns regarding accuracy and 
reliability of ET, the (VO2 max.) is now more commonly 
accepted as a direct measure of cardio-respiratory endurance 
during exercise of increasing intensity [1,36-38]. Virtually 
all studies have shown a strong correlation between total 
body VO2  max and survival in CHF [38]. Nevertheless, the 
majority of trials have accessed the benefits of ET in 
patients’ with CHF not only by exercise duration but more 
importantly by peak VO2 [1,29-40].  
  Improvement in peak exercise capacity and an improved 
ability to tolerate sub maximal exercise represent clinically 
important and expected outcomes in stable patients with mild 
to moderate heart failure. Recent work of follow-up in over 
150 CHF patients demonstrated a significant increase in both 
peak VO2 and muscle strength, but no improvement in 6-
minute walk distance [28]. The possible mechanisms respon-
sible for the ET induced increase in peak VO2 represent an 
assimilation of several peripheral factors like reduced 
vasoconstriction, improved oxygen extraction and metabolic 
function at the active skeletal muscles
1. Time to ventilatory 
derived anaerobic threshold and oxygen con-sumption at this 
threshold are also increased with training, suggesting dela-
yed reliance on anaerobic pathways for energy production [1, 
18]. 
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EXERCISE TRAINING AND IMPROVEMENT IN 
MYOCARDIAL FUNCTION 
  The effects of exercise training on both LV systolic and 
diastolic function are so far not conclusive and require larger 
trials with longer follow-up. Belardinelli and co-workers 
reported an improvement in diastolic filling rate that was 
related with an increase in cardiac index at peak exercise 
[36]. Similarly, ET duration is an important factor in 
implementing the improvement in cardiac function [40]. This 
suggests that long term ET is required to achieve central 
hemodynamic changes at any given workload. The severity 
of heart failure and the nature of training also modulate the 
effects of ET. Bank and associates demonstrated that 
improvement in endothelium-dependent vasodilatation after 
forearm exercise training is less readily obtained in patients’ 
with heart failure than in the control subjects [41]. 
  ELVD-CHF, a multi-centre randomised controlled trial 
involving 90 patients with CHF demonstrated that long term 
moderate ET in stable CHF patients with severe LV systolic 
dysfunction has an anti-remodelling effect on LV volumes 
with significant improvement in ejection fraction [42]. In 
addition, ET in patients’ with post-infarction LV dysfunction 
does not have any harmful effect on LV volumes; rather it 
attenuates the remodelling process
41. Importantly emerging 
investigations [17, 43-44]
  have shown that the infiltration/ 
activation of monocytes contribute to the development of 
remodelling and heart failure. ET intervenes at various stages 
of the inflammatory process in patients’ with CHF and exerts 
a favourable control of remodelling by reducing the major 
circulating pro-inflammatory cytokines and their soluble 
receptor.  
  Growing evidence supports the notion that ET, often 
combined with endurance exercise, is
  efficient in patients 
with CHF [45].
  In two small separate cross-over
  studies, 
Maiorana and co-workers [46-47]
  demonstrated that CT 
improved
  aerobic capacity, muscle strength and peripheral 
endothelial
  function. These data were later confirmed in a 
larger study
 involving a total of 39 CHF patients [48]. Others 
have shown increased
  skeletal muscle mitochondrial ATP 
production rate and higher
 capillary density, as well as anti-
inflammatory
 effects [49-50].  
EXERCISE TRAINING AND VENTILATORY 
FUNCTION 
  The early onset of dyspnoea in CHF patients’ is mainly 
caused by altered ventilatory response to exercise due to 
increased dead space ventilation resulting from pulmonary 
congestion. Presence of cardiac insufficiency in CHF 

















Fig. (1). Suggested mechanisms underlying the progression of heart failure.  
KEY: CO= cardiac output, HR= heart rate, EDV= end diastolic volume, ESV= end systolic volume, NO= nitric oxide, SV= stroke volume, 
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reflected by a peripheral catabolic state as evidenced by 
increased lactate production and acidosis [51]. The lactic 
acidosis (mediated by the metabolites) directly or indirectly 
may stimulate hyperventilation by acting on reflex control at 
rest and on exercise, leading to a reduction in arterial PCO2. 
Similarly, stimulation of chemoreceptors may show oscil-
lation in respiration, heart rate and blood pressure modulated 
by cerebral circulation [51]. Lactic acidosis would be present 
at rest only in extreme circumstances.  
  Although the origin of dyspnoea is multifactorial, the 
increased ventilation in CHF plays an important role and is 
characterised by both rapid and shallow respiration. How-
ever measurement of ventilatory exchange during exercise 
shows that the ratio of dead space/tidal volume (VD/VT) is 
increased suggesting that ventilation/perfusion defects 
develop during exercise [1]. Furthermore early activation of 
muscle ergoreflex contributes to an excessive increase in 
sympathetic activation and exercise hyper-ventilation [51]. 
ET largely attenuates the abnormal venti-latory response to 
exercise in CHF patients by a delay in blood lactate 
accumulation, better ventilation/perfusion matching and 
attenuation of the ergoreflex activation [1, 51]. 
EXERCISE TRAINING AND IMPROVEMENT OF 
SKELETAL MUSCLE FUNCTION 
  Histological and metabolic abnormalities of muscle cells, 
and skeletal muscle wasting have been described in CHF 
patients [52]. Anaerobic metabolism is found to occur early 
in patients with HF undertaking ET. This was found to be 
independent to the reduced blood flow to the muscle in this 
subset of patients [32]. Duscha et al, suggested that in 
patients with HF, an increase in capillary density would be a 
favourable adaptation. Moreover, the authors noticed a 
significant reduction in the microvascular density in patients’ 
with CHF without major differences in other histologic and 
biochemical aerobic markers [53]. The skeletal muscle 
dysfunction in heart failure is due to atrophy of muscle fibre, 
a relative decrease in oxidative type-I fibres, loss of micro-
vasculature, decrease in enzymes of oxidative metabolism, 
and attenuation of mitochondrial surface density and size [3, 
30]. ET has been shown in part to correct the skeletal muscle 
abnormalities in these patients. Several trials using a limb 
training model have documented improvements in muscle 
functions as measured by muscle strength, exercise time, 
phosphocreatinine re-synthesis and depletion rates, adeno-
sine diphosphate concentration and intracellular pH [7,54].  
EXERCISE TRAINING AND IMPROVEMENT OF 
ENDOTHELIAL FUNCTION 
  CHF patients have a subnormal peripheral blood flow 
response to exercise. This is not only due to reduced cardiac 
output but also to an abnormal peripheral vasodilatory 
response. The abnormal peripheral vasodilatory response to 
ischaemic challenge could be due to a variety of stimuli 
including isotonic and isometric exercise, adrenergic bloc-
kade, and ischemia and arterial vasodilatation [51-55]. An 
additional mechanism suggested involves vascular stiffness 
secondary to increased vascular sodium content as evidenced 
by the fact that the capillary basement membrane may be   
 
thickened in HF and that the vascular responsiveness is 
partially improved by diuretic therapy [7, 54]. Endothelium 
dependent dilatation of the vasculature is impaired in HF as 
demonstrated by the reduction in the release of nitric oxide 
in response to acetylcholine [7, 55]. The release of nitric 
oxide, an important mediator of the flow-dependent vaso-
dilatation is stimulated by exercise in healthy individuals but 
seems to be attenuated in CHF patients. This contributes to 
reduction in peripheral vasodilatation and thus tissue 
perfusion. This has been supported by the fact that blockade 
of nitric oxide synthesis reduces the flow to exercising 
muscle and L-arginine (nitric oxide precursor) supplemen-
tation improves the abnormal vasodilatation in response to 
ischemia in patients’ with HF [23].  
  Exercise training also enhances oxidative capacity of the 
skeletal muscle and corrects endothelial dysfunction of the 
skeletal musculature in ischemic and dilated cardiomyopathy 
[23]. This contributes to the reduction of peripheral resis-
tance and improvement in stroke volume. This in part could 
explain the improvement of myocardial perfusion observed 
even in the absence of changes in coronary artery diameter 
[43]. Although it is well known that ET improves vasodilator 
function it is not clear whether other markers such as 
reduced vasoconstrictor tone and improved large vessel func-
tion via enhanced endothelial vasodilator function contri-
butes to this. 
EXERCISE TRAINING AND ENDOTHELIAL 
PROGENITOR CELLS (EPC) 
  There is relatively very little information available in the 
literature on the effect of ET on circulating EPC in patient 
with CHF. Single centred studies with small number of 
patients have shown that intensive and moderate ET for long 
periods increased circulating levels of EPC in normal 
subjects [56]. Increased numbers of circulating endothelial 
progenitor cells (EPC) are associated with improved vascular 
function. Endothelial progenitor cells (EPCs) were experi-
mentally shown to incorporate into sites of neovascula-
rization and home to sites of endothelial denudation [56]. 
Increased oxygen demand may represent an important bene-
ficial outcome of physical exercise, supporting the notion 
that increased numbers of EPC correlate with cardiovascular 
health.  
  Dimmeler’s group previously reported the inverse 
relationship between the patients with coronary artery 
disease (CAD) and circulating EPC levels and function [57]. 
Furthermore, they also studied whether this impairment 
extends to bone marrow–derived
  mononuclear cells (BM-
MNCs) in patients with chronic ischemic
  cardiomyopathy 
(ICMP). They found a significantly fewer colony-forming 
capacity of BM-MNCs from patients with ICMP, along with 
reduced migratory response to challenge in vitro. The 
authors further reported reduced neovascularization capacity 
despite
 similar contents of hematopoietic stem cells in vivo 
[58]. Similarly Goette et al reported that moderate-to-severe 
CHF is not associated with elevated EPC levels in the 
systemic circulation. They also could not demonstrate a mea-
surable cardiac uptake of EPC in this cohort [59]. 
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EXERCISE TRAINING AND IMPROVEMENT OF 
QUALITY OF LIFE 
  CHF patients experience progressive decline in the 
quality of life (QOL), limiting their routine daily activity due 
to the early onset of dyspnoea and fatigue. In addition 
depression and isolation are common in these patients. Even 
patients with stable heart failure suffer reduced QOL as 
symptoms relief is not complete [1].  
  Only a few studies of heart failure patients participating 
in exercise training programme have included the QOL 
questionnaire in their study protocol. In addition the QOL 
measurement tools vary and the results are inconsistent. The 
majority of the trials used “Minnesota Living with Heart 
Failure questionnaire” that assesses disease-specific health-
related QOL and its effects on daily life [1, 60]. However 
few trials used dyspnoea-fatigue index, [8, 61] a self 
administered 5-point Likert scale instrument measuring 
magnitude of each component; the specific dyspnoea-provo-
king task, the pace with which the task is performed and the 
patient’s general functional capacity [8]. Majority of the 
trials that measured QOL in HF patients ranged in sample 
size from 25 to 99, undergoing 3 to 12 months of exercise 
training. Majority of the trials show a significant 
improvement in QOL and improvement in exercise capacity, 
[1,33] with few trials demonstrating no improvement in 
QOL [62]. The earlier mentioned difference in outcome 
could be explained on the basis of different protocols and 
variable tools for the measurement of QOL. 
  It is still not clear, whether ET in HF has any long term 
effects on QOL as no strong correlation exists between 
measures of health related QOL and central hemodynamic 
abnormalities and exercise intolerance [7]. Nevertheless, ET 
is proving to be an effective treatment for improving QOL as 
patients become more tolerant of exertion; and experience 
less fatigue and dyspnoea and become comfortable perfor-
ming tasks of daily living. 
EXERCISE TRAINING AND SURVIVAL 
  Currently there is no published large randomised 
controlled trial studying the long term clinical effectiveness 
of ET in CHF patients. Recently published literature com-
prises of mostly single centred experience containing small 
number of patients with short follow up. Belardinelli & co-
workers analysed 99 patients with a mean follow up of 3.4 
yrs. In their study, patients in the exercise training group had 
fewer deaths (all deaths were cardiac deaths) (P=0.01); fewer 
hospitalizations for chronic heart failure (P=0.02); fewer 
cardiac events (P=0.006); increased peak oxygen consump-
tion per unit time (P<0.001) and thallium uptake (P<0.001); 
and improved qualify of life at 2, 14, and 26 months [29].  
  Whellan & colleagues identified 70 patients in their 
database with HF who participated in Cardiac Rehabilitation 
(CR) program. Participation in CR> 6 sessions was asso-
ciated with significantly improved survival (P < .0001). The 
authors suggested a dose response with improved survival 
benefit for patients with CHF participating in cardiac 
rehabilitation [63].  
 Tenenbaum  et al followed 42 CHF patients for over 3 yrs 
and reported increased survival benefits in patients that 
continued ET for 3 yrs compared to those who stopped after 
1.6 yrs [64]. Smart and Marwick in 2004 identified a total of 
81 studies in a meta-analysis (30 were randomized controlled 
trials, five nonrandomized controlled trials, nine randomized 
crossover trials, and 37 longitudinal cohort studies) and 
reported that mortality was not directly related to 60,000 
patient-hours of exercise training. During the training and 
follow-up periods of the randomized controlled trials, there 
were 56 combined (deaths or adverse events) events in the 
exercise groups and 75 combined events in the control 
groups (odds ratio [OR] = 0.98; 95% confidence interval 
[CI]: 0.61 to 1.32; P = 0.60). During this same period, 26 
exercising and 41 non-exercising subjects died (OR = 0.71; 
95% CI: 0.37 to 1.02; P = 0.06). The authors suggested that 
ET is safe and effective in patients with heart failure. The 
risk of adverse events may be reduced, but further studies are 
required to determine whether there are any survival benefits 
[64]. 
SUMMARY 
  As discussed earlier, cardiac failure itself is a syndrome 
of circulatory failure, secondary to ventricular dysfunction. 
This primarily ventricular
  dysfunction is followed by a 
variety of neurohumoral, peripheral
  circulatory, skeletal 
muscle, and respiratory adaptations which
  determine the 
syndrome's clinical presentation and prognosis more
 than the 
primary ventricular dysfunction
  itself. Traditionally, avoi-
dance of exercise was thus advocated in all forms and stages 
of heart failure [65].
  However, there is now
  evidence that 
inactivity leads to a further deterioration of remaining
 
functional capacity. Published data so far on one hand is 
difficult to interpret with regard to the benefits of exercise 
duration and intensity on the outcome in chronic heart failure 
patients. Yet, more recently it has been shown
 that selected 
patients with compensated stable CHF
  can safely follow a 
training programme, thereby improving exercise
  tolerance 
and functional
 status [66-67].  
  Poor left ventricular function is not necessarily 
synonymous with CHF, which is characterized by reduced
 
tissue oxygen supply. The best method of evaluating the 
disease
  state of a patient with a compromised heart is 
cardiopulmonary
 exercise testing, that is, the measurement of 
oxygen consumption
  (VO2 in ml/kg/min) during exercise. 
With ET, the observed improvements are sometimes small, 
but may have a major impact on quality of life in CHF 
patients. The
  difference after training is reflected in the 
patient's ability
 to cope with the physical demands of day to 
day activity, thus
 preventing the need for continuous bed rest 
and the loss of independence
 which often results in the need 
for chronic care.  
  The interpretation of reported results of dynamic exercise 
training in CHF is frequently complicated by the lack of 
sufficient
  power and the non-randomized trial design. 
Moreover, the incorporation
 of home-based activities and the 
use of unsophisticated tools
 for resistance training, such as 
elastic rubber bands, could
  lead to less strict adherence to 
prescribed activity. This set-up allowed close assessment of
 
exercise intensity and work-volume and the early detection 
of
 adverse effects. Despite the fact that a cautious approach 
is still advocated
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training in CHF patients,
 scientifically correct evaluation of 
the safety of CT might
 be able to shift paradigms in the near 
future. Sustained isometric
 weightlifting at high intensity (80 
to 90% of 1RM) and its possible
 detrimental effects are very 
distinct from dynamic resistive
  exercise prescription in 
cardiovascular patients. Several investigators
  have shown 
that the acute haemodynamic responses during resistance
 
exercise in CHF patients were similar or lower than for 
aerobic
 exercise of comparable intensity. 
  Contraindications for CHF patients participating in such 
ET programme are the same as for patients
 with coronary 
artery disease [66]. While observing these contraindications,
 
the studies reviewed showed no major complications during 
or shortly
 after exercise. By and large, all patients on optimal 
medical therapy for CHF and with stable heart failure should 
be advocated exercise training as this will compliment 
medical therapy. However, patients with acute CHF, struc-
tural valvular pathology and unstable coronary artery disease 
should be medically managed and optimized prior to 
embarking on exercise training. Patients with NYHA class 
IV symptoms should be optimized and class downgraded 
medical therapy. However, in patients with stable class IV 
symptoms trial of ET under careful supervision and moni-
toring particularly during the initial training period is 
important. Telemetry monitoring during
 these early sessions 
is also recommended in such a case. 
  Further research is thus necessary to confirm the role of 
ET as a treatment for patients with CHF,
 and to determine 
the most appropriate intensity, mode, and duration
  of 
training. Training can comprise overall endurance training
 
monitored by heart rate, interval training based on percen-
tage
 of maximum exercise level, or strength training. It has 
been suggested [67-68]
  that muscle groups
  can be trained 
simultaneously or consecutively.
 For training to be effective, 
the intensity should be sufficiently
 high, and the frequency 
should be at least three times a week.
 Initial training, lasting 
for at least six weeks, should be followed
 by a maintenance 
training regimen, since all improvements are
 reversible. An 
active lifestyle should be
 promoted.  
  In conclusion, exercise training in CHF patients has some 
merits and as discussed in this review, the changes induced 
by exercise at molecular level are well documented. How-
ever, how these changes translate into symptom improve-
ment and QOL transformation is still not clear; in part due to 
lack of standardisation of the different ET protocols used. 
But before such patients
  can participate in a training 
programme, it is important to clarify
 the pathophysiology of 
their heart failure and thus identify their
  limiting factors. 
Finally the patient's individual profile requires
 definition: the 
training programme must be tailored to the patient's
 specific 
limitations and desired level of
 activity. Nevertheless, with 
the existing pool of evidence ET may safely be advocated to 
patients by health professionals keeping in view of their HF 
pathophysiology; whilst awaiting results from more robust 
large randomised studies.  
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